• Research Tree
  • Features
  • Pricing
  • Events
  • Reg.News
  • Short Interest
  • Explore Content
    • Explore

      • Providers
        • Providers

          • Free/Commissioned
          • High Net Worth Offering
          • Institutional Offering

          Free/Commissioned

          Research that is free to access for all investors. Companies commission these providers to write research about them.

          View Research

          What is our Main Bundle Offering?

          Brokers who write research on their corporate clients and make it available through our main bundle offering.

          View Research

          What is Institutional?

          Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.

          View Research
      • Regions
        • Regions

          • UK
          • Rest of EMEA
          • N America
          • APAC
          • LatAm
      • Exchanges
        • Exchanges

          • Aquis Apex
          • Australian Securities Exchange
          • Canadian Securities Exchange
          • Euronext Paris
          • London Stock Exchange (domestic)
          • SIX Swiss Exchange
      • Sectors
        • Sector Coverage

          • Building & Construction
          • Discretionary Personal Goods
          • Discretionary Retail
          • Energy
          • Health
          • Investment Trusts
          • Media
          • Resources
          • Technology
      • Small / Large Cap
        • Small / Large Cap

          • UK100
          • UK250
          • UK Smallcap
          • UK Other Main Markets
          • Other
  • Login
  • Sign Up
LIVE

Event in Progress:

Join Here ×

working
  • 09 Jan 2026

Proven Leadership Returns As Kevin Guest Reappointed CEO At USNA; Maintain $39 Price Target


USANA Health Sciences (USNA:NYSE) | 0 0 0.0%


  • Sidoti & Company
    • Anthony C. Lebiedzinski

    • 10 pages


 

Yesterday, USNA announced that Kevin Guest, age 63, is back as CEO of the company after a nearly three-year absence from the top leadership role, during which time he was executive chairman. Mr. Guest succeeds Jim Brown, who was CEO since July 2023 and previously was part of the management team for more than 15 years. Mr. Brown will remain as an advisor to USNA for a yet to be defined period. Mr. Guest was co-CEO from August 2015 and was then named CEO in November 2016, a position he held until June 2023. During his prior tenure leading the company, USNA achieved record results in revenue (2018) and EPS (2020). We expect Mr. Guest's primary objective to be to return the company to sustainable growth by reversing recent trends in its core direct selling business. At the same time, we expect management to be focused on further diversifying revenue through continued growth of Hiya (acquired in 2024) and Rise Bar (acquired in 2022), as well as pursuing potential additional acquisitions, which are not included in our financial projections. All in all, with Mr. Guest being employed by USNA full time since February 2004 in various roles, we think his deep and extensive knowledge of the company will result in a seamless transition. We maintain our $39 price target, based on 14x our 2027 EPS estimate of $2.76. Our moderate risk rating on USNA factors in the company's strong balance sheet and ample free cash flow generation, which we expect to average about $2 per share annually in 2026-2027.

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here
See all the research we have on this company.

Proven Leadership Returns As Kevin Guest Reappointed CEO At USNA; Maintain $39 Price Target


USANA Health Sciences (USNA:NYSE) | 0 0 0.0%


  • Published: 09 Jan 2026
  • Author: Anthony C. Lebiedzinski
  • Pages: 10
  • Sidoti & Company


Yesterday, USNA announced that Kevin Guest, age 63, is back as CEO of the company after a nearly three-year absence from the top leadership role, during which time he was executive chairman. Mr. Guest succeeds Jim Brown, who was CEO since July 2023 and previously was part of the management team for more than 15 years. Mr. Brown will remain as an advisor to USNA for a yet to be defined period. Mr. Guest was co-CEO from August 2015 and was then named CEO in November 2016, a position he held until June 2023. During his prior tenure leading the company, USNA achieved record results in revenue (2018) and EPS (2020). We expect Mr. Guest's primary objective to be to return the company to sustainable growth by reversing recent trends in its core direct selling business. At the same time, we expect management to be focused on further diversifying revenue through continued growth of Hiya (acquired in 2024) and Rise Bar (acquired in 2022), as well as pursuing potential additional acquisitions, which are not included in our financial projections. All in all, with Mr. Guest being employed by USNA full time since February 2004 in various roles, we think his deep and extensive knowledge of the company will result in a seamless transition. We maintain our $39 price target, based on 14x our 2027 EPS estimate of $2.76. Our moderate risk rating on USNA factors in the company's strong balance sheet and ample free cash flow generation, which we expect to average about $2 per share annually in 2026-2027.

More Content

More Content

2026 Outlook: Direct Selling Segment Rebound, Growth At Hiya To Drive 2H:26-2027 EPS Gains; A Solid Balance Sheet Positions USNA Well For Potential Additional M&A; Maintain $39 Price Target

Companies: USANA Health Sciences

Sidoti & Company

2Q:25 Sales And EPS Comfortably Ahead Of Our Forecasts; With Reaffirmed Annual Guidance, Our Fine-Tuned EPS Estimates Still Imply Annual Gains; Maintain $61 Price Target

Companies: USANA Health Sciences

Sidoti & Company

Updated 2026 EPS Estimates Still Reflect A Healthy Rebound After A Tough 2025; Maintain $39 Price Target As We Shift Our Valuation Basis To Our New 2027 EPS Forecast

Companies: USANA Health Sciences

Sidoti & Company

3Q:25 Results In Line With Pre-Announcement; Fine Tune 2025 EPS Estimate Given Updated Guidance; Maintain $39 Price Target Based On Expected Rebound In 2026, Solid Financials

Companies: USANA Health Sciences

Sidoti & Company

Lower EPS Estimates, Price Target To $39 (From $61) After USNA Pre-Announces 3Q:25 Results; Expect Rebound In 2026 With Improved Brand Partner Productivity; Highlight Solid Balance Sheet

Companies: USANA Health Sciences

Sidoti & Company
Research Tree
Useful Links
  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub
  • Stock Pick League
  • iOS and Android Apps
Account
  • Login
  • Join Now
  • Contact
  • Follow us on Linkedin
  • Follow us on X

© Research Tree 2026

  • Apple Store
  • Play Store
  • Terms of Service
  • Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top
  • Home
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest Tracker
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Exchanges
      • Aquis Apex
      • Australian Securities Exchange
      • Canadian Securities Exchange
      • Euronext Paris
      • London Stock Exchange (domestic)
      • SIX Swiss Exchange
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • ETFs
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Investment Trusts
      • Leisure, Tourism & Travel
      • Media
      • Open-ended Funds
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Trusts, ETFs & Funds
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Actinver
      • Actio Advisors
      • Allenby Capital
      • Asset TV
      • Astris Advisory
      • Atrium Research
      • Baden Hill
      • BlytheRay
      • BNP Paribas Exane - Sponsored Research
      • Bondcritic
      • Bowsprit Partners Limited
      • Brand Communications
      • Brokerlink
      • BRR Media
      • Calvine Partners
      • Capital Access Group
      • Capital Link
      • Capital Markets Brokers
      • Cavendish
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Doceo
      • Edison
      • EM Spreads
      • Engage Investor
      • Equity Development
      • eResearch
      • First Equity
      • Five Minute Pitch TV
      • focusIR
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • goetzpartners securities Limited
      • Golden Section Capital
      • GreenSome Finance
      • GSBR Research
      • H2 Radnor
      • Hardman & Co
      • Holland Advisors
      • Hypothesis Research
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Longspur Clean Energy
      • Mello Events
      • Messari Research
      • Morphose Capital Partners
      • MUFG Corporate Markets IR
      • Nippon Investment Bespoke Research UK
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Optimo Capital
      • Panmure Liberum
      • Paul Scott
      • Peel Hunt
      • PIWORLD / Progressive
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • RaaS Research Group
      • Research Dynamics
      • Research Tree
      • Resolve Research
      • SEAL Advisors Ltd
      • ShareSoc
      • Shore Capital
      • Sidoti & Company
      • Small Cap Consumer Research LLC
      • StockBox
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Curious Compounder
      • The Edge Group
      • The Life Sciences Division
      • ThinkFront
      • Tring Triangle
      • Trinity Delta
      • Turner Pope Investments
      • UK Investor Group
      • ValueTrack
      • Vox Markets
      • VRS International S.A. - Valuation & Research Specialists (VRS)
      • VSA Capital
      • Winterflood Securities
      • World Platinum Investment Council
      • Yaru Investments
      • Yellowstone Advisory
      • Zacks Small Cap Research
      • Zeus Capital
    • High Net Worth Offering
      • ABG Sundal Collier
      • ACF Equity Research
      • Acquisdata
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane - Sponsored Research
      • Canaccord Genuity
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • First Berlin
      • First Equity
      • First Sentinel
      • Greenwood Capital Partners
      • Hannam & Partners
      • Hybridan
      • ISTAR Capital
      • Kemeny Capital
      • Longspur Clean Energy
      • Louis Capital
      • Magnitogorsk Iron and steel works
      • Medley Global Advisors
      • Northland Capital Partners
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • QuotedData Professional
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • Tennyson Securities
      • The Life Sciences Division
      • Turner Pope Investments
      • VSA Capital
      • Whitman Howard
      • xxxxxx_deleted
      • Yellowstone Advisory
      • Zeus Capital
    • Institutional Offering
      • ABG Sundal Collier
      • ACF Equity Research
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • BNP Paribas Exane
      • Bondcritic
      • Canaccord Genuity
      • Capital Access Group
      • Capital Link
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • Edison
      • First Berlin
      • First Equity
      • First Sentinel
      • Five Minute Pitch TV
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • Golden Section Capital
      • Goodbody
      • Greenwood Capital Partners
      • Hannam & Partners
      • Holland Advisors
      • Hybridan
      • InterAxS Global
      • Investec Bank
      • ISTAR Capital
      • Kepler | Trust Intelligence
      • Longspur Clean Energy
      • Numis
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • Peel Hunt
      • QuotedData
      • QuotedData Professional
      • Research Dynamics
      • Research Tree
      • Shard Capital
      • Shore Capital
      • Sidoti & Company
      • Singer Capital Markets
      • Small Cap Consumer Research LLC
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • StockBox
      • Tamesis Partners
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Life Sciences Division
      • Tring Triangle
      • ValueTrack
      • Velocity Trade
      • VSA Capital
      • Winterflood Securities
      • World Platinum Investment Council
      • Zacks Small Cap Research
      • Zeus Capital
  • Contact
  • Sign Up
  • Sign In